Spanish Society of Primary Care Physicians (SEMERGEN) and Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) survey on the management of patients with inflammatory bowel disease

被引:3
|
作者
Ginard, Daniel [1 ,2 ]
Ricote, Mercedes [3 ,4 ]
Nos, Pilar [2 ,5 ]
Pejenaute, M. Elena [3 ,4 ]
Sans, Miquel [2 ,6 ]
Fontanillas, Noelia [4 ,7 ,8 ]
Acosta, Manuel Barreiro-de [2 ,9 ]
机构
[1] Hosp Univ Son Espases, Serv Aparato Digest, Palma De Mallorca, Spain
[2] GETECCU, Bilbao, Spain
[3] Ctr Salud Mar Baltico, Med Familiar & Comunitaria, Madrid, Spain
[4] Grp Trabajo Aparato Digest SEMERGEN, Madrid, Spain
[5] Hosp Univ & Politecn Valencia, Serv Med Digest, Valencia, Spain
[6] Ctr Med Teknon ISADMU, Serv Aparato Digest, Barcelona, Spain
[7] Ctr Salud Bezana, Med Familiar & Comunitaria, Santa Cruz De Bezana, Cantabria, Spain
[8] Grp Digest SEMERGEN, Madrid, Spain
[9] Complejo Hosp Univ Santiago De Compostela, Serv Aparato Digest, Santiago De Compostela, A Coruna, Spain
[10] SEMERGEN, Madrid, Spain
来源
GASTROENTEROLOGIA Y HEPATOLOGIA | 2023年 / 46卷 / 08期
关键词
Primary care; Gastroenterology; Inflammatory bowel disease; Management; Diagnosis; Coordination; QUALITY-OF-CARE; DIAGNOSTIC DELAY; GUIDELINES; BURDEN; UPDATE;
D O I
10.1016/j.gastrohep.2022.10.023
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Introduction: Collaboration between Primary Care (PC) and Gastroenterology in inflammatory bowel disease (IBD) is crucial to provide high-quality healthcare. The aim of this study is to analyse the relationship between PC and gastroenterologists at a national level in order to identify areas for improvement in the management of patients with inflammatory bowel disease ( IBD) and how to address them, with the aim of subsequently developing concrete proposals and projects between SEMERGEN and GETECCU. Methods: Descriptive, observational, cross-sectional study, was carried out using an anonymous online questionnaire between October 2021 and March 2022. Results: A total of 157 surveys from Gastroenterology and 222 from PC were collected. 43.8% and 34.3% of gastroenterologists and family practitioners, respectively, considered that there was a good relationship between the units. The level of knowledge from family practitioners regarding different aspects of IBD out of 10 was: clinical 6.67 +/- 1.48, diagnosis 6.47 +/- 1.46, treatment 5.63 +/- 1.51, follow-up 5.53 +/- 1.68 and complications 6.05 +/- 1.54. The perception of support between both units did not exceed 4.5 on a scale from 0 to 10 in either of the surveys. The most highly voted improvement proposals were better coordination between the units, implementation of IBD units, and nursing collaboration. Conclusion: There are deficiencies in the relationship between PC and Gastroenterology with special dedication to IBD that require the efforts of the scientific societies that represent themfor greater coordination with the development of joint protocols and agile, fast, and effective communication channels. (c) 2022 The Authors. Published by Elsevier Espana, S.L.U. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
引用
收藏
页码:647 / 656
页数:10
相关论文
共 50 条
  • [21] Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis on the use of anti-tumor necrosis factor drugs in inflammatory bowel disease
    Luis Cabriada, Jose
    Vera, Isabel
    Domenech, Eugeni
    Barreiro-de Acosta, Manuel
    Esteve, Maria
    Gisbert, Javier P.
    Panes, Julia
    Gomollon, Fernando
    GASTROENTEROLOGIA Y HEPATOLOGIA, 2013, 36 (03): : 127 - 146
  • [22] Recommendations of the Spanish Working Group on Crohn's disease and ulcerative colitis (GETECCU) on pouchitis in ulcerative colitis. Part 2: Treatment (vol 43, pg 649, 2020)
    Barreiro-de Acosta, Manuel
    Marin-Jimenez, Ignacio
    Rodriguez-Lago, Iago
    Guarner, Francisco
    Espin, Eloy
    Ferrer Bradley, Isabel
    Gutierrez, Ana
    Beltran, Belen
    Chaparro, Maria
    Gisbert, Javier P.
    Nos, Pilar
    GASTROENTEROLOGIA Y HEPATOLOGIA, 2021, 44 (04): : 320 - 320
  • [23] Vedolizumab in the Treatment of the Ulcerative Colitis and the Crohn's disease, a Consensus of the Working Group "Chronic Inflammatory Bowel Disease" of the Austrian Society for Gastroenterology and Hepatology
    Novacek, G.
    Dejaco, C.
    Groechenig, H. P.
    Hoegenauer, C.
    Knoflach, P.
    Miehsler, W.
    Moschen, A.
    Petritsch, W.
    Vogelsang, H.
    Tilg, H.
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2016, 54 (05): : 456 - 467
  • [24] The State of Health Care and Health Care Paths in Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis)
    Preiss, J. C.
    Blumenstein, I.
    Zeuzem, S.
    Zeitz, M.
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2009, 47 (06): : 529 - 530
  • [25] Questionnaire Survey for Inflammatory Bowel Disease Patients in Japan; A Web-Based Japan, Crohn's Disease, Ulcerative Colitis, Patients Survey
    Matsumoto, Takayuki
    Imai, Keita
    Goda, Yuki
    Fujimitsu, Yuki
    Kajioka, Toshifumi
    Kihara, Hideaki
    Funaki, Yuji
    Imaki, Shigeru
    Ueno, Masato
    CROHNS & COLITIS 360, 2023, 5 (04)
  • [26] Inflammatory bowel diseases. Crohn's disease and ulcerative colitis
    Fischer, S.
    Rath, T.
    Neurath, M. F.
    INTERNIST, 2018, 59 (07): : 681 - 692
  • [27] Risk of ulcerative colitis and Crohn's disease among offspring of patients with chronic inflammatory bowel disease
    Orholm, M
    Fonager, K
    Sorensen, HT
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 1999, 94 (11): : 3236 - 3238
  • [28] Effect of Obesity on Inflammatory Bowel Disease (Ulcerative Colitis vs Crohn's Disease)
    Dasu, Neethi
    Khalid, Yaser
    Blair, Brian
    Walters, Richard
    Chhoun, Christopher
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S678 - S679
  • [29] Experimental Inflammatory Bowel Disease: Lessons for the Treatment of Crohn's Disease and Ulcerative Colitis
    Ivan Fuss
    Pediatric Research, 1999, 45 : 746 - 746
  • [30] Dietary Supplement Therapies for Inflammatory Bowel Disease: Crohn's Disease and Ulcerative Colitis
    Parian, Alyssa
    Limketkai, Berkeley N.
    CURRENT PHARMACEUTICAL DESIGN, 2016, 22 (02) : 180 - 188